Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.54 |
| ▸ | APP | P05067 | 5/20 | 0.54 |
| ▸ | CTSD | P07339 | 3/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037100 | 0.92 | BACE1 (0.52) | BACE1APPCTSDBACE2 | |
| SCHEMBL5071310 | 0.92 | BACE1 (0.55) | BACE1APPCTSDBACE2 | |
| SCHEMBL5036929 | 0.91 | BACE1 (0.62) | BACE1APPCTSDBACE2 | |
| SCHEMBL5036923 | 0.91 | BACE1 (0.62) | BACE1APPCTSDBACE2 | |
| SCHEMBL5072987 | 0.91 | BACE1 (0.55) | BACE1APPCTSDBACE2 | |
| SCHEMBL3414047 | 0.90 | BACE1 (0.62) | BACE1APPCTSDBACE2 | |
| SCHEMBL5037372 | 0.89 | BACE1 (0.57) | BACE1APPCTSDBACE2 | |
| SCHEMBL5038640 | 0.88 | BACE1 (0.60) | BACE1APPCTSDBACE2 | |
| SCHEMBL5038541 | 0.88 | BACE1 (0.52) | BACE1APPCTSDBACE2 | |
| SCHEMBL5036952 | 0.88 | BACE1 (0.60) | BACE1APPCTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345082-B2 | Phosphinic acids | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1685142-B1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1685142-A1 | PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044830-A1 | PHOSPHINIC ACIDS DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107341-A1 | Phosphinic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107341-A1 | Phosphinic acids | BACE1, PSEN1, PSEN2 | BACE1 1/4885APP 5/4885CTSD 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.